Physicians' Academy for Cardiovascular Education

SGLT-2 inhibition reduces mortality and hospitalization for HF in patients with diabetes and PAD

Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients With Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Subodh Verma (St Michael's Hospital, University of Toronto, Canada)

News - Nov. 15, 2017

Main results


EMPA was associated with profound reductions in mortality and HHF in patients with T2DM and PAD.

The substantial risk reductions observed in the vulnerable subgroup of patients with T2D and PAD from the EMPA-REG OUTCOME trial, have important translational implications.


Discussant Renato D. Lopes (Duke University Medical Center, Durham, NC, USA) said that with new drugs such as GLP-1 receptor agonists and SGLT-2 inhibitors, a new era has begun of better outcomes for patients with DM beyond glucose control. The benefits of empagliflozin are preserved in patients with and without PAD, with no signal of increase risk of amputation.

This is different from other SGLT-2 inhibitor programs (CANVAS) and deserves further investigation

An integrated management team of endocrinologists, cardiologists, vascular surgeons, primary care physicians, and other health care providers is the new paradigm of treatment of patients with DM.


- Our reporting is based on the information provided at the AHA 2017 congress -

Share this page with your colleagues and friends: